Longfellow, I totally agree each to their own opinion on the impact to the genetic sub groups. My opinion is based on Presentations and published works by Liau and Prins and others clearly showing to my opinion that it helps the mesenchymal group and not much for the others. Presentations by Liau and then Prins in 2016 show this and Liau again in spring 2019. Published papers by same researchers say the same thing. The presentations still available on youtube and the papers in national library of medicine. Hope it helps more but I'm basing my opinions on work from the UCLA group. Liau states that all the long survivors were in the mesenchymal group and little or no impact to the proneural. As the UCLA work is why I am long I'm sticking with their research and opinions. As in all markets each must form their own opinion.
As to direct the Bosch presentation is in the ihub links an he imo clearly states all the direct work is early and needs more trials. At minute 18:59 to 19:10 or so he speaks of can't talk the phase 1 direct detail as a paper is in the works which at least I have not yet seen. Imo direct has great promise but many years and lots of $ away. My guess year 2025 at best
With as long as the sap took to write I sure hope they included sub groups. Liau said they do it on all their gbm patients, as principal investigator I hope she had at least some input or the company may have just pushed her out of the picture? Hope not
News 
Market Data 
Discover 
